Amgen

{{Short description|American multinational biopharmaceutical company}} {{Use mdy dates|date=July 2025}} {{Infobox company | name = Amgen Inc. | former_names = Applied Molecular Genetics (1980–1983) | logo = Amgen.svg | logo_size = 250px | image = Amgenheadquarters.jpg | image_size = 250px | image_caption = Headquarters in Thousand Oaks, California | type = Public | ISIN = {{ISIN|sl=n|pl=y|US0311621009}} | traded_as = {{unbulleted list|{{NASDAQ|AMGN}}|Nasdaq-100 component|DJIA component|S&P 100 component|S&P 500 component}} | industry = Biotechnology | founded = {{start date and age|1980|4|8}} | hq_location = {{nowrap|Thousand Oaks, California, U.S.}} | key_people = {{unbulleted list|Robert A. Bradway (chairman, president & CEO)|Howard Y. Chang (CSO)}} | products = {{hlist|Aimovig|Aranesp|Blincyto|Epogen|Kineret|Enbrel|Kyprolis|Neulasta|Neupogen|Nplate|Parsabiv|Prolia|Repatha|Sensipar/Mimpara|Vectibix|Xgeva}} | revenue = {{increase}} {{US$|36.8 billion|link=yes}} (2025) | operating_income = {{increase}} {{US$|9.08 billion}} (2025) | net_income = {{increase}} {{US$|7.71 billion}} (2025) | assets = {{decrease}} {{US$|90.6 billion}} (2025) | equity = {{increase}} {{US$|8.66 billion}} (2025) | num_employees = 31,500 (2025) | website = {{URL|https://amgen.com/}} | footnotes = <ref name=10K>{{Cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0000318154/000031815426000010/amgn-20251231.htm |title=2025 Annual Report (Form 10-K) |date=February 13, 2026 |publisher=U.S. Securities and Exchange Commission}}</ref> }} '''Amgen Inc.''' is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, '''Applied Molecular Genetics'''.

The company's major products are Prolia and XGEVA (denosumab) to treat osteoporosis and bone diseases ($6.6 billion in total 2025 revenues), Repatha (evolocumab) to treat hyperlipidemia ($3.0 billion in 2025 revenues), Otezla (apremilast) to treat psoriasis and psoriatic arthritis ($2.3 billion in 2025 revenues), Enbrel (etanercept) to treat autoimmune diseases ($2.2 billion in 2025 revenues), Evenity (romosozumab) to treat osteoporosis ($2.1 billion in 2025 revenues), Tepezza (teprotumumab) to treat Graves' ophthalmopathy ($1.9 billion in 2025 revenues), Blincyto (blinatumomab) to treat acute lymphoblastic leukemia ($1.6 billion in 2025 revenues), Nplate (romiplostim) to regulate platelet production ($1.5 billion in 2025 revenues), Tezspire (tezepelumab) to treat asthma ($1.5 billion in 2025 revenues), Kyprolis (carfilzomib) to treat cancer ($1.4 billion in 2025 revenues), Aranesp (darbepoetin alfa) to stimulate erythropoiesis ($1.4 billion in 2025 revenues), Krystexxa (pegloticase) to treat gout ($1.3 billion in 2025 revenues), and Vectibix (panitumumab), a monoclonal antibody ($1.2 billion in 2025 revenues).<ref name=10K/>

Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.<ref>{{cite web |title=Amgen Pipeline |url=https://www.amgenpipeline.com/ |website=Amgen Pipeline}}</ref>

The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.<ref name=10K/>

The company is ranked 134th on the ''Fortune'' 500<ref>{{cite web | url=https://fortune.com/company/amgen/ | title=Fortune: Amgen | publisher=Fortune | url-access=subscription}}</ref> and 202nd on the ''Forbes'' Global 2000.<ref>{{cite web | title=Forbes: Amgen | url=https://www.forbes.com/companies/amgen/ | work=Forbes}}</ref>

In 2020, the company was added to the Dow Jones Industrial Average (DJIA).<ref>{{Cite web |title=Salesforce.com, Amgen and Honeywell International Set to Join Dow Jones Industrial Average |url=https://press.spglobal.com/2020-08-24-Salesforce-com-Amgen-and-Honeywell-International-Set-to-Join-Dow-Jones-Industrial-Average |access-date=2026-01-21 |website=News Release Archive |language=en}}</ref>

== History == thumb|right|AMGen corporate logo, 1983 [[File:Macri Amgen.jpg|thumb|Argentine president Mauricio Macri meets with heads of Amgen, in 2018.]] In April 1980, Amgen was founded in Thousand Oaks as Applied Molecular Genetics.<ref>{{cite news | url=https://www.latimes.com/archives/la-xpm-2007-aug-09-fi-amgen9-story.html | title=Amgen's troubles loom large over hometown | first=Daniel | last=Costello | work=Los Angeles Times | date=August 9, 2007}}</ref> Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin.<ref name="Walsh">{{cite web |url=https://pharmaphorum.com/views-and-analysis/a_history_of_amgen/ |last=Walsh |first=Robin |title=A history of: Amgen |website=pharmaphorum.com |date=October 27, 2010}}</ref>

Winston Salser, a molecular biologist at UCLA recruited its initial scientific advisory board consisting of Norman Davidson, Leroy Hood, Arnold Berk, John Carbon, Robert Schimke, Arno Motulsky, Marvin H. Caruthers, and Dave Gibson.<ref>{{cite journal | url=https://www.nature.com/articles/nbt0612-481 | title=George Rathmann 1927–2012 | journal=Nature Biotechnology | date=June 7, 2012 | volume=30 | issue=6 | page=481 | doi=10.1038/nbt0612-481 }}</ref> In October 1980, Amgen named George Rathmann its first president and chief executive officer.<ref name="Walsh" /><ref>{{Cite news | url=https://www.nytimes.com/2012/04/24/business/george-rathmann-chief-of-amgen-dies-at-84.html | title=George Rathmann, Amgen Chief, Dies at 84 | first=Andrew | last=Pollack | work=The New York Times | date=April 24, 2012}}</ref>

{{Anchor|Krin-Amgen}}On June 17, 1983, Amgen became a public company via an initial public offering, selling two million common shares and raising nearly $40 million.<ref>{{cite web |url=https://www.inc.com/magazine/19830901/2878.html |title=Small Company Initial Public Offerings: June 1983 |work=Inc |date=September 1, 1983}}</ref><ref>{{cite news |url=https://www.thestreet.com/investing/stocks/amgen-this-beaten-down-blue-chip-is-priced-to-own-14930489 |last=Ward |first=Nicholas |title=Amgen: This Beaten Down Blue Chip Is Priced To Own |work=TheStreet.com |date=April 21, 2019}}</ref><ref>{{cite news |url=https://archive.seattletimes.com/archive/?date=20020513&slug=amgen130 |title=Shrewd science: Biotech giant Amgen's success reflects its savvy corporate style |last=Timmerman |first=Luke | work=The Seattle Times |date=May 13, 2002}}</ref> That same year, after more than two years of work, an Amgen research team led by Fu-Kuen Lin found and cloned the erythropoietin gene, a protein created in the kidney that stimulates red blood cell production. Lin's team created what would become Epogen (epoetin alfa).<ref>{{cite news |url=https://www.latimes.com/archives/la-xpm-1989-06-02-fi-1020-story.html |last=Bate |first=James |title=Biotech Detective Scores Coup : Amgen scientist spent years searching for the key to producing EPO. | work=Los Angeles Times |date=June 2, 1989}}</ref><ref name="Kim">{{cite book |url=https://books.google.com/books?id=Qah8DwAAQBAJ |last=Kim |first=Rachel |title=Economics and management in the biopharmaceutical industry in the USA: evolution and strategic change |publisher=Routledge |isbn=9781351012690 |location=London |pages=2002–2003 |date=2019}}</ref>

In June 1984, Amgen and Kirin Brewery Company formed a joint venture giving Kirin the rights to Epogen in Japan, while Amgen retained United States distribution rights; both companies had the opportunity to expand to other countries.<ref>{{cite news |url=https://www.nytimes.com/1984/06/15/business/kirin-and-amgen-hormone-venture.html|title=Kirin and Amgen Hormone Venture|work=The New York Times|agency=Reuters|date=June 15, 1984|url-access=subscription|archive-url=https://web.archive.org/web/20150524153615/https://www.nytimes.com/1984/06/15/business/kirin-and-amgen-hormone-venture.html|archive-date=May 24, 2015|url-status=live}}</ref> This joint venture gave way in 2017 to a new joint venture, Kirin-Amgen, which bought out Kirin Holdings stake.<ref>{{Cite news |url=https://www.reuters.com/article/idUSKBN1D00YO/|title=Japan's Kirin cashes out of Amgen drug joint venture|date=October 31, 2017|agency=Reuters}}</ref> A year later, Amgen researcher Larry Souza and his team cloned granulocyte colony-stimulating factor (G-CSF), leading to the development of Neupogen (filgrastim).<ref name="Kim" /><ref>{{cite news |url=https://www.latimes.com/archives/la-xpm-1997-05-20-fi-60727-story.html |last=Murphy |first=Barbara |title=Souza to Run Research at Biotech King Amgen |work=Los Angeles Times | date=May 20, 1997}}</ref><ref>{{cite journal |last1=Bendall |first1=Linda J. |last2=Bradstock |first2=Kenneth F. |date=August 2014 |title=G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent |journal=Cytokine & Growth Factor Reviews |volume=25 |issue=4 |pages=355–367 |doi=10.1016/j.cytogfr.2014.07.011 |pmid=25131807 |doi-access=free}}</ref>

In October 1988, Gordon Binder was named CEO, succeeding George Rathmann.<ref>{{cite news |url=https://www.latimes.com/archives/la-xpm-1995-10-17-fi-58041-story.html |title=Gordon M. Binder, chief executive of Amgen... |work=Los Angeles Times |date=October 17, 1995}}</ref> The following year, in 1989, Amgen received approval for the first recombinant human erythropoetin product, Epogen (epoetin alfa).<ref>{{cite news |url=https://www.washingtonpost.com/wp-srv/business/amgen-anemia-drugs/index.html |title=Amgen and its erythropoietin drugs |newspaper=The Washington Post |date=July 19, 2012}}</ref>

In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.<ref>{{Cite news |url=https://www.nytimes.com/1991/02/22/business/an-fda-approval-for-amgen.html |last=Pollack |first=Andrew |title=An F.D.A. Approval for Amgen |work=The New York Times |date=February 22, 1991 | url-access=limited |issn=0362-4331}}</ref>

Amgen opened a new manufacturing facility in Puerto Rico, in March 1993, which later became the company's flagship manufacturing site.<ref>{{Cite news |url=https://www.latimes.com/archives/la-xpm-1993-08-17-fi-24667-story.html |title=Amgen to Open Puerto Rico Plant Despite Tax Credit Cut : Biotechnology: Analysts say the benefit reduction does not alter expectations of strong long-term growth for the Thousand Oaks giant. |last=Apodaca |first=Patrice |website=Los Angeles Times |date=August 17, 1993 | url-access=limited}}</ref>

In 1994, Amgen became the fifth company to receive the National Medal of Technology and Innovation from the United States Department of Commerce, in recognition of its work developing medicines to improve quality of life for kidney and cancer patients.<ref>{{cite news |url=https://www.latimes.com/archives/la-xpm-1994-09-16-fi-39443-story.html |title=Amgen, Phone Entrepreneur Win Medal of Technology |last=Nathans |first=Aaron |work=Los Angeles Times |date=September 16, 1994 | url-access=limited}}</ref> Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp (darbepoetin alfa).<ref>{{cite news |url=https://www.forbes.com/forbes/2001/0903/118.html?sh=7bd567cd5244 |title=A Biotech Wonder Grows Up |work=Forbes |date=September 3, 2001 | url-access=limited}}</ref>

=== 2000–2014 === Binder was succeeded as CEO by Kevin W. Sharer in 2000.<ref>{{Cite news |url=https://money.cnn.com/2000/05/11/news/amgen/index.htm |archive-url=https://web.archive.org/web/20021220100816/http://money.cnn.com/2000/05/11/news/amgen/index.htm |url-status=dead |archive-date=December 20, 2002 |title=Amgen names new CEO | publisher=CNN | date=May 11, 2000}}</ref> Robert A. Bradway became Amgen's president and chief executive officer in May 2012, following Sharer's retirement.<ref>{{cite press release | url=https://www.prnewswire.com/news-releases/kevin-sharer-amgen-chairman-and-ceo-announces-plan-to-retire-with-robert-bradway-to-become-ceo-on-may-23-2012-sharer-will-continue-as-chairman-of-the-board-until-end-of-2012-135689093.html | title=Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 | publisher=PR Newswire | date=December 15, 2011}}</ref>

In June 2010, Amgen received approval by the Food and Drug Administration for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.<ref>{{cite web |title=Drug Approval Package |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125320s0000TOC.cfm | publisher=Food and Drug Administration}}</ref> In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.<ref>{{cite web |title=HIGHLIGHTS OF PRESCRIBING INFORMATION – Prolia (denosumab) |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0000lbl.pdf | publisher=Food and Drug Administration | date=June 2010}}</ref> In November 2010, the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.<ref>{{cite press release | url=https://www.prnewswire.com/news-releases/fda-approves-xgeva-to-help-prevent-cancer-related-bone-injury-109200654.html | title=FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury | publisher=PR Newswire | date=November 19, 2010}}</ref> The clinical trials primarily enrolled patients with breast or prostate cancer.

In March 2011, Amgen acquired a manufacturing facility near Dublin, Ireland.<ref>{{cite news |url=https://www.irishtimes.com/business/health-pharma/amgen-to-buy-pfizer-plant-1.873076 |title=Amgen to buy Pfizer plant |newspaper=The Irish Times |date=March 11, 2011}}</ref>

Amgen opened an affiliate in China in 2013.<ref>{{cite news |last=Becker |first=Zoey |title=Amgen partners with Fosun to bring Otezla, Parsabiv to patients in China |url=https://www.fiercepharma.com/pharma/amgen-partners-fosun-pharma-bring-psoriasis-chronic-kidney-disease-medicines-country |work=Fierce Pharma | publisher=Questex | date=June 27, 2022}}</ref><ref>{{cite news |url=https://www.genengnews.com/news/amgen-expands-china-presence-cancer-rd-with-2-7b-beigene-collaboration/ |title=Amgen Expands China Presence, Cancer R&D with $2.7B BeiGene Collaboration | work=Genetic Engineering and Biotechnology News |last=Philippidis |first=Alex |date=November 1, 2019}}</ref>

In November 2014, the company halted all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.<ref>{{cite web | title=Amgen Halts Rilotumumab Trials in Advanced Gastric Cancer |url=https://www.genengnews.com/news/amgen-halts-rilotumumab-trials-in-advanced-gastric-cancer/ | work=Genetic Engineering and Biotechnology News | date=November 24, 2014}}</ref> Also in November 2014, the company, in conjunction with AstraZeneca, reported positive results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.<ref>{{cite news |title=Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca | url=https://www.genengnews.com/news/brodalumabs-no-turkey-in-phase-iii-amgen-and-astrazeneca/ | work=Genetic Engineering and Biotechnology News | date=November 26, 2014}}</ref> In the same month, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore.<ref>{{cite news |url=https://www.biopharma-reporter.com/Article/2014/11/21/Amgen-launches-200m-biomanufacturing-facility-in-Singapore |title=Amgen launches $200m biomanufacturing facility in Singapore |last=Brennan |first=Zachary |date=November 21, 2014 |work=BioPharma-Reporter}}</ref> Blincyto (blinatumomab) was approved by the FDA in December of that year.<ref>{{cite journal | last1=Przepiorka |first1=Donna |last2=Ko |first2=Chia-Wen |last3=Deisseroth |first3=Albert |last4=Yancey | first4=Carolyn L. |last5=Candau-Chacon |first5=Reyes |last6=Chiu |first6=Haw-Jyh |last7=Gehrke |first7=Brenda J. | last8=Gomez-Broughton |first8=Candace |last9=Kane |first9=Robert C. |last10=Kirshner |first10=Susan |last11=Mehrotra | first11=Nitin |last12=Ricks |first12=Tiffany K. |last13=Schmiel |first13=Deborah |last14=Song |first14=Pengfei | last15=Zhao |first15=Ping |date=September 15, 2015 |title=FDA Approval: Blinatumomab |journal=Clinical Cancer Research |volume=21 |issue=18 |pages=4035–4039 |doi=10.1158/1078-0432.CCR-15-0612 |issn=1557-3265 |pmid=26374073 | s2cid=207687724 |last16=Zhou |first16=Qing |last17=Farrell |first17=Ann T. |last18=Pazdur |first18=Richard}}</ref><ref>{{cite news |url=https://ascopost.com/issues/december-15-2014/fda-approves-blinatumomab-to-treat-rare-form-of-acute-lymphoblastic-leukemia/ |title=FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia |work=American Society of Clinical Oncology |date=December 15, 2014}}</ref>

=== 2015–2020 === In March 2015, the company announced that it would license its Phase II candidate drug AMG 714 to Celimmune, which will develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.<ref>{{cite news |title=Celimmune Licenses Amgen's AMG 714 for Celiac Disease |url=https://www.genengnews.com/news/celimmune-licenses-amgens-amg-714-for-celiac-disease/ | work=Genetic Engineering and Biotechnology News | date=March 2, 2015}}</ref> In August 2015, Repatha (evolocumab) was approved by the FDA.<ref>{{cite news |url=https://www.nytimes.com/2015/08/28/health/fda-approves-another-in-a-new-class-of-cholesterol-drugs.html |last=Kolata |first=Gina |title=F.D.A. Approves Repatha, a Second Drug for Cholesterol in a Potent New Class |work=The New York Times |date=August 27, 2015 | url-access=limited}}</ref>

In September 2016, the company announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.<ref>{{cite news | url=https://www.genengnews.com/news/amgen-buys-rights-to-myeloma-bite-immunotherapy-from-boehringer-ingelheim/ | title=Amgen Buys Rights to Myeloma BiTE Immunotherapy from Boehringer Ingelheim | work=Genetic Engineering and Biotechnology News |date=September 1, 2016}}</ref> Also in September, the FDA approved Amjevita (adalimumab-atto).<ref name="Staton">{{cite news |url=https://www.fiercepharma.com/pharma/amgen-s-humira-biosim-amjevita-passes-fda-milestone-long-road-to-market |title=Amgen's Humira biosim, Amjevita, passes FDA milestone on long road to market | last=Staton |first=Tracy |work=Fierce Pharma | publisher=Questex |date=September 23, 2016}}</ref> The FDA approved Parsabiv in February 2017<ref>{{cite news |url=https://www.biopharmadive.com/news/amgen-fda-approval-parsabiv/435760/ |last=Bell | first=Jacob |title=Amgen secures FDA approval for hormone drug |work=BioPharma Dive | publisher=Informa | date=February 8, 2017}}</ref> and Mvasi (bevacizumab-awwb) in September.<ref name="Mvasi approval">{{cite web | url=https://www.gabionline.net/biosimilars/news/FDA-approves-bevacizumab-biosimilar-Mv |title=FDA approves bevacizumab biosimilar Mvasi asi |website=GaBI Online |date=September 22, 2017}}</ref>

In July 2018, Amgen began constructing a biomanufacturing plant at its campus in West Greenwich, Rhode Island.<ref>{{cite news | url=https://www.fiercepharma.com/manufacturing/amgen-breaks-ground-200m-next-gen-biopharma-plant-rhode-island | title=Amgen breaks ground on $200M next-gen biopharma plant in Rhode Island | first=Joseph | last=Keenan | work=Fierce Pharma | publisher=Questex | date=August 1, 2018}}</ref><ref>{{cite news |url=https://www.pharmaceutical-technology.com/projects/amgens-next-generation-bio-manufacturing-plant-rhode-island/ |title=Amgen's New Bio-manufacturing Plant, Rhode Island, US |website=Pharmaceutical Technology |date=August 10, 2018}}</ref>

In January 2019, Evenity (romosozumab) received approval in Japan,<ref>{{cite web |url=https://www.thepharmaletter.com/article/evenity-gets-first-ever-approval-in-japan |title=Evenity gets first ever approval, in Japan |website=The Pharma Letter |date=January 9, 2019}}</ref><ref>{{cite news |url=https://www.fiercebiotech.com/biotech/amgen-gets-first-ok-for-evenity-japan-as-fda-panel-looms |last=Taylor |first=Phil |title=Amgen gets first OK for Evenity in Japan as FDA panel looms | work=FierceBiotech | date=January 9, 2019}}</ref> followed by FDA approval in April.<ref>{{cite news |url=https://www.fiercepharma.com/pharma/amgen-s-bone-drug-evenity-approved-by-fda-expected-caveat |last=Liu |first=Angus |title=Amgen bone drug Evenity finally wins its FDA green light, but there's a catch |work=Fierce Pharma | publisher=Questex |date=April 10, 2019}}</ref> In June, Kanjinti (trastuzumab-anns) was approved by the FDA.<ref name="Kanjinti approval">{{cite web |url=https://www.centerforbiosimilars.com/view/fda-approves-amgens-trastuzumab-biosimilar-kanjinti |title=FDA Approves Amgen's Trastuzumab Biosimilar, Kanjinti |website=The Center For Biosimilars |date=June 13, 2019}}</ref>

In December 2019, the FDA approved Avsola (infliximab-axxq).<ref>{{cite news |url=https://www.healio.com/news/rheumatology/20191206/fda-approves-avsola-fourth-remicade-biosimilar |title=FDA approves Avsola, fourth Remicade biosimilar |work=www.healio.com |date=December 6, 2019}}</ref>

In September 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation.<ref>{{cite news | url=https://www.targetedonc.com/news/fda-grants-amg-510-fast-track-designation-for-kras-g12c-nsclc | title=FDA Grants AMG 510 Fast Track Designation for KRAS G12C+ NSCLC | first=Lisa | last=Astor | publisher=targetedonc.com | date=September 9, 2019}}</ref>

In April 2020, Amgen established Amgen K.K. as the company's wholly owned affiliate in Japan.<ref>{{cite news |url=https://www.reuters.com/article/brief-amgen-establishes-wholly-owned-aff/brief-amgen-establishes-wholly-owned-affiliate-in-japan-idUSFWN2BO1OX |title=BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan |work=Reuters|date=April 1, 2020}}</ref><ref>{{cite news |url=https://www.fiercepharma.com/pharma-asia/amgen-wades-deeper-into-asia-by-assuming-full-control-astellas-japanese-jv |title=Amgen wades deeper into Asia with full control of an Astellas Japanese JV |last=Liu |first=Angus |work=Fierce Pharma | publisher=Questex |date=January 23, 2020}}</ref> The company announced in July that the United States Court of Appeals for the Federal Circuit had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by the United States District Court for the District of New Jersey and rejected Sandoz's attempt to invalidate the patents on Enbrel.<ref>{{cite news |url=https://www.reuters.com/article/us-amgen-novartis-enbrel/amgen-defeats-novartis-appeal-over-arthritis-drug-enbrels-patents-idUSKBN2426EG |title=Amgen defeats Novartis appeal over arthritis drug Enbrel's patents | first=Jonathan | last=Stempel | editor-first1=Bill | editor-last1=Berkrot | editor-first2=Dan | editor-last2=Grebler | work=Reuters|date=July 1, 2020}}</ref>

In August 2020, Amgen, Takeda Pharmaceutical Company, and AbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen.<ref>{{cite news |last=Liu |first=Angus |title=AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study | url=https://www.fiercepharma.com/pharma/abbvie-amgen-and-takeda-test-anti-inflammatory-drugs-joint-covid-19-study | work=Fierce Pharma | publisher=Questex | date=August 3, 2020}}</ref>

In September 2020, Amgen and Eli Lilly and Company announced a global manufacturing collaboration for COVID-19 antibody therapies.<ref>{{cite news | url=https://www.fiercepharma.com/manufacturing/eli-lilly-amgen-join-forces-to-scale-production-covid-19-antibody-cocktails | last=Blankenship | first=Kyle | title=Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails | work=Fierce Pharma | publisher=Questex |date=September 17, 2020}}</ref>

In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (including immunotherapy and/or chemotherapy).<ref>{{cite news |url=https://ascopost.com/news/february-2021/phase-ii-codebreak-100-validates-early-benefit-for-kras-inhibitor-in-nsclc/ | last=Helwick |first=Caroline |title=Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC | work=American Society of Clinical Oncology | date=February 1, 2021}}</ref> Amgen, the Global Coalition for Adaptive Research, and Eisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19.<ref>{{cite news | url=https://www.statnews.com/2020/11/10/adaptive-trials-covid19-amgen-eisai/ | last=Ross | first=Casey | title=Drug companies deliver a vote of confidence in adaptive trial for Covid-19 |work=STAT | date=November 10, 2020}}</ref>

In November 2020, Amgen, Takeda, and UCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19.<ref>{{cite news | url=https://www.reuters.com/article/us-health-coronavirus-treatment-trial/covid-rd-alliance-launches-trial-of-amgen-ucb-takeda-drugs-idUSKBN28A2Y7 | title=COVID R&D Alliance launches trial of Amgen, UCB, Takeda drugs |last=Beasley |first=Deena | work=Reuters | date=November 30, 2020}}</ref> Amgen also announced that it would terminate its collaboration with Cytokinetics and transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.<ref>{{cite news | url=https://www.biopharmadive.com/news/amgen-terminate-deal-cytokinetics-heart-failure-omecamtiv/589572/ | last=Gardner | first=Jonathan | title=Amgen cuts Cytokinetics loose after heart drug disappointment |work=BioPharma Dive | date=November 23, 2020}}</ref> Amgen and AstraZeneca announced positive topline results from a Phase 3 trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma.<ref>{{cite news |url=https://www.pulmonologyadvisor.com/home/meetings/chest-2021/navigator-trial-outcomes-for-tezepelumab-use-in-severe-uncontrolled-asthma/ | last=Dembeck |first=Lauren |title=NAVIGATOR Trial Outcomes for Tezepelumab Use in Severe, Uncontrolled Asthma | work=Pulmonology Advisor |date=October 18, 2021}}</ref>

In December 2020, the FDA granted breakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation.<ref>{{cite news | url=https://www.fiercebiotech.com/biotech/amgen-plans-2020-filing-for-fda-approval-kras-drug-sotorasib | last=Taylor | first=Nick Paul | title=Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib | work=FierceBiotech | date=December 8, 2020}}</ref> Also in December 2020, the FDA approved Riabni (rituximab-arrx), a biosimilar to Rituxan.<ref name="Riabni approval">{{cite news |url=https://www.clinicaloncology.com/FDA-Watch/Article/12-20/FDA-Approves-Riabni-Third-Biosimilar-to-Rituxan/61514 |title=FDA Approves Riabni, Third Biosimilar to Rituxan |work=Clinical Oncology News |date=December 18, 2020}}</ref><ref>{{cite press release | url=https://www.prnewswire.com/news-releases/fda-approves-amgens-riabni-rituximab-arrx-a-biosimilar-to-rituxan-rituximab-301195492.html | title=FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab) | publisher=PR Newswire | date=December 17, 2020}}</ref>

In April 2021, the company acquired Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion.<ref>{{Cite press release | url=https://www.prnewswire.com/news-releases/amgen-successfully-completes-acquisition-of-five-prime-therapeutics-301270601.html | title=Amgen Successfully Completes Acquisition Of Five Prime Therapeutics | publisher=PR Newswire | date=April 16, 2021}}</ref><ref>{{Cite news |url=https://www.biospace.com/article/releases/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash/ |title=Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash | work=BioSpace | date=March 4, 2021}}</ref><ref>{{Cite news |url=https://www.reuters.com/article/us-five-prime-m-a-amgen/amgen-adds-gastric-cancer-drug-candidate-in-1-9-billion-five-prime-therapeutics-deal-idUSKBN2AW1PT |title=Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market | first=Manojna | last=Maddipatla | work=Reuters|date=March 4, 2021}}</ref><ref>{{Cite news |url=https://www.biospace.com/how-amgen-acquired-five-prime-for-1-9-billion-beating-out-a-dozen-others |title=How Amgen Acquired Five Prime for $1.9 Billion, Beating Out a Dozen Others |website=BioSpace |date=March 19, 2021}}</ref>

In the March 2021, Amgen acquired Rodeo Therapeutics for $720 million.<ref>{{Cite web |url=https://www.biospace.com/article/amgen-to-buy-rodeo-therapeutics-in-721-million-deal/ |title=In Second Acquisition this Month, Amgen Buys Rodeo for $721 Million | work=BioSpace | date=March 31, 2021}}</ref><ref>{{Cite press release | url=https://www.prnewswire.com/news-releases/amgen-to-acquire-rodeo-therapeutics-corporation-301258957.html | title=Amgen to Acquire Rodeo Therapeutics Corporation | publisher=PR Newswire | date=March 30, 2021}}</ref>

In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation.<ref>{{cite news | url=https://ascopost.com/issues/june-25-2021/fda-approves-sotorasib-for-kras-g12c-mutated-nsclc/ | title=FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC | work=American Society of Clinical Oncology | date=June 25, 2021}}</ref> Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe<ref>{{cite news | url=https://www.onclive.com/view/sotorasib-approved-in-europe-for-kras-g12c-mutated-advanced-nsclc | title=Sotorasib Approved in Europe for KRAS G12C–Mutated Advanced NSCLC | first=Kristi | last=Rosa | work=Onclive | date=January 10, 2022}}</ref> and Japan.<ref>{{cite news | url=https://www.cancernetwork.com/view/sotorasib-earns-approval-in-japan-for-kras-g12c-nsclc | title=Sotorasib Earns Approval in Japan for KRAS G12C+ NSCLC | first=Audrey | last=Sternberg | publisher=cancernetwork.com | date=January 20, 2022}}</ref> The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer.<ref name="Lumakras approval">{{cite news |url=https://ascopost.com/issues/june-25-2021/fda-approves-sotorasib-for-kras-g12c-mutated-nsclc/ |title=FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC | work=American Society of Clinical Oncology |date=June 25, 2021}}</ref>

In June 2021, Amgen and Kyowa Kirin announced joint plans to develop and commercialize a treatment for atopic dermatitis.<ref>{{cite news |url=https://www.fiercebiotech.com/biotech/amgen-reunites-longtime-partner-kyowa-kirin-400m-dermatitis-deal |title=Amgen reunites with longtime partner Kyowa Kirin in $400M dermatitis deal |last=Idrus |first=Amirah Al |work=FierceBiotech |date=June 1, 2021}}</ref> In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases.<ref>{{cite news |url=https://www.fiercebiotech.com/biotech/meet-neumora-arch-s-500m-amgen-partnered-play-for-targeted-future-neuroscience-r-d |title=Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D |last=Taylor |first=Nick Paul |work=FierceBiotech |date=October 7, 2021}}</ref><ref>{{cite news |url=https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-invest-100-million-softbank-backed-neumora-2021-10-07/ |title=Amgen to invest $100 million in SoftBank-backed Neumora | first=Manas | last=Mishra | editor-first=Shailesh | editor-last=Kuber |work=Reuters|date=October 7, 2021}}</ref> Amgen began construction on a new biomanufacturing plant in New Albany, Ohio, in November.<ref>{{cite news |url=https://www.ns-healthcare.com/news/amgen-new-biomanufacturing-facility-in-us/ |title=Amgen breaks ground on new biomanufacturing facility in Ohio, US |work=NS Healthcare |date=November 8, 2021}}</ref> In December, the FDA approved Amgen and AstraZeneca's Tezspire (tezepelumab) for severe asthma.<ref name="Dunleavy">{{cite news |url=https://www.fiercepharma.com/pharma/amgen-astrazeneca-win-nod-for-tezspire-severe-asthma-drug-has-blockbuster-potential-analyst |title=Amgen, AstraZeneca score FDA nod for blockbuster hopeful asthma drug Tezspire |last=Dunleavy |first=Kevin |work=Fierce Pharma | publisher=Questex |date=December 20, 2021}}</ref> The FDA also approved Amgen's Otezla for adults with plaque psoriasis of any severity level.<ref>{{cite news |url=https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-expanded-use-amgens-psoriasis-drug-2021-12-20/ |title=U.S. FDA approves expanded use of Amgen's psoriasis drug | first=Dania | last=Nadeem | editor-first=Ramakrishnan |editor-last=M. | work=Reuters|date=December 20, 2021}}</ref>

Amgen announced a research collaboration in January 2022 with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.<ref>{{cite news |url=https://www.fiercebiotech.com/biotech/amgen-chooses-generate-for-1-9b-biobucks-deal-to-churn-out-up-to-10-multi-modality-drug |title=Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs |last=Armstrong |first=Annalee |work=FierceBiotech |date=January 6, 2022}}</ref><ref>{{cite news |last=Philippidis |first=Alex |title=Amgen, Generate Launch Up-to-$1.9B Protein Therapeutics Collaboration |url=https://www.genengnews.com/topics/drug-discovery/therapeutics/protein-therapeutics/amgen-generate-launch-up-to-1-9b-protein-therapeutics-collaboration/ | work=Genetic Engineering and Biotechnology News | date=January 6, 2022}}</ref> The company also launched a multi-target collaboration with Arrakis Therapeutics to identify novel targeted RNA degrader therapeutics.<ref>{{cite news |url=https://www.fiercebiotech.com/biotech/amgen-teams-up-arrakis-to-destroy-disease-causing-rna-75m-research-deal |title=JPM 2022: Amgen teams up with Arrakis to destroy disease-causing RNA in $75M research deal | last=Armstrong |first=Annalee | work=FierceBiotech | date=January 11, 2022}}</ref><ref>{{cite news | url=https://www.biopharmadive.com/news/amgen-arrakis-rna-degrader-small-molecule/616997/ | title=Amgen partners with Arrakis to develop drugs aimed at RNA |last=Pagliarulo | first=Ned |work=BioPharma Dive | publisher=Informa | date=January 11, 2022}}</ref> The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.<ref>{{cite news | url=https://www.biospace.com/article/amgen-and-plexium-ink-500m-targeted-protein-degradation-therapies-pact/ | title=Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact | last=Shasteen | first=Hayley |work=BioSpace | date=February 3, 2022}}</ref><ref>{{cite news | url=https://www.fiercebiotech.com/biotech/amgen-lines-up-500m-biobucks-deal-plexium-for-protein-degradation-therapies | title=Amgen enters hot protein degradation field with $500M biobucks deal with Plexium |last=LaHucik |first=Kyle |work=FierceBiotech | date=February 3, 2022}}</ref> Also in February, Amgen issued its first green bond to fund various environmentally friendly initiatives across the company.<ref>{{cite news | url=https://www.sfvbj.com/news/weekly-news/amgen-issues-green-bond/ | title=Amgen Issues 'Green Bond' | last=Pequeño IV | first=Antonio |work=San Fernando Valley Business Journal | date=February 23, 2022}}</ref><ref>{{cite news | url=https://www.bloomberg.com/news/articles/2022-03-29/amgen-mulls-more-green-bonds-after-robust-interest-in-debut | title=Amgen Mulls More Green Bonds After 'Robust Interest' in Debut | last=Mutua |first=David Caleb | work=Bloomberg News | date=March 29, 2022 | url-access=subscription}}</ref> The company broke ground on a new manufacturing facility in Holly Springs, North Carolina, in March.<ref>{{cite news | url=https://wraltechwire.com/2022/03/07/amgen-expects-new-holly-springs-plant-to-be-a-permanent-home/ |title=Amgen expects new Holly Springs plant to be 'a permanent home' |last=Parker |first=Jason |work=WRAL-TV |date=March 7, 2022 }}</ref><ref>{{cite news | url=https://www.genengnews.com/topics/bioprocessing/amgen-breaks-ground-on-nc-biomanufacturing-facility/ | last=Sterling | first=John |title=Amgen Breaks Ground on NC Biomanufacturing Facility | work=Genetic Engineering and Biotechnology News | date=March 11, 2022}}</ref>

In September 2022, data from a late-stage study showed the company's cancer pill Lumakras (sotorasib) beating out chemotherapy. This was the first approved drug in the set of treatments that target KRAS, among the most common generic mutations found in cancers. The drug was approved in 2021 with a list price of $17,900 per month.<ref>{{Cite news | url=https://www.wsj.com/articles/new-cancer-drug-beats-chemotherapy-in-study-11662996694 | last=Walker | first=Joseph | title=New Cancer Drug Beats Chemotherapy in Study | work=The Wall Street Journal | date=September 12, 2022 | url-access=subscription | issn=0099-9660}}</ref>

In October 2022, the company acquired ChemoCentryx, the maker of Tavneos—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associated vasculitis, for $3.7 billion in an all-cash deal.<ref>{{cite news |last=Walker |first=Joseph |date=August 4, 2022 |title=Amgen to Buy ChemoCentryx for $3.7 Billion |url=https://www.wsj.com/articles/amgen-to-buy-chemocentryx-for-3-7-billion-11659614401 |work=The Wall Street Journal |url-access=subscription}}</ref><ref>{{Cite press release | url=https://www.prnewswire.com/news-releases/amgen-successfully-completes-acquisition-of-chemocentryx-301654916.html | title=AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX | publisher=PR Newswire | date=October 20, 2022}}</ref><ref>{{Cite news | url=https://www.bizjournals.com/losangeles/news/2022/10/21/amgen-completes-chemocentryx-purchase.html | title=Amgen completes purchase of ChemoCentryx for $3.7 billion | first=I-Chun | last=Chen | work=American City Business Journals | date=October 21, 2022 | url-access=subscription}}</ref>

In October 2023, Amgen acquired Horizon Therapeutics, specializing in drugs for rare diseases, for $27.8 billion.<ref>{{Cite news | url=https://www.reuters.com/markets/deals/amgen-completes-278-bln-horizon-deal-2023-10-06/ | title=Amgen completes $27.8 billion Horizon deal | work=Reuters| date=October 6, 2023}}</ref><ref>{{cite news | url=https://www.reuters.com/markets/deals/amgen-set-buy-biotech-firm-horizon-26-bln-valuation-bloomberg-news-2022-12-12/ | last1=Mishra | first1=Manas | last2=Satija | first2=Bhanvi | title=Amgen dives deeper into rare disease drugs with $27.8 BLN Horizon deal | work=Reuters| date=December 12, 2022}}</ref>

In November 2023, Amgen announced plans to use artificial intelligence in partnership with Amazon Web Services to help discover and create medicines and use the Amazon SageMaker machine learning service to help with the manufacturing process.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20231128600885/en/AWS-Joins-Forces-With-Amgen-on-Generative-AI-Solutions-to-Accelerate-Advanced-Therapies | title=AWS Joins Forces With Amgen on Generative AI Solutions to Accelerate Advanced Therapies | publisher=Business Wire | date=November 28, 2023}}</ref>

In March 2025, data for the drug Tezspire (tezepelumab), showed the best results for treating chronic rhinosinusitis with nasal polyps.<ref>{{Cite news | url=https://www.fiercepharma.com/pharma/amgen-astrazeneca-tezspire-sinusitis-data-spark-best-disease-talk-amid-sanofi-gsk | last=Liu | first=Angus | title=Amgen, AZ Tezspire sinusitis data invite 'best-in-disease' talk | work=Fierce Pharma | publisher=Questex | date=March 3, 2025}}</ref>

Also in March 2025, Amgen announced the start of two late-stage trials for MariTide, an anti-obesity medication candidate.<ref>{{Cite news |url=https://www.bloomberg.com/news/articles/2025-03-05/amgen-starts-final-stage-studies-of-its-monthly-obesity-drug | last=Garde | first=Damian | title=Amgen Starts Final-Stage Studies of Its Monthly Obesity Drug | work=Bloomberg News | date=March 5, 2025 | url-access=subscription}}</ref><ref>{{Cite news | url=https://www.cnbc.com/2025/03/05/amgen-weight-loss-drug-maritide-starts-two-phase-three-trials.html | last=Constantino | first=Annika Kim | title=Amgen starts two critical late-stage trials for weight loss drug MariTide | work=CNBC | date=March 5, 2025}}</ref> In June 2025, the company noted that it had to reduce the dosage of the drug to avoid side effects such as vomiting.<ref>{{Cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/low-start-dose-amgen-experimental-weight-loss-drug-limits-side-effects-2025-06-23/ | title=Amgen experimental weight-loss drug needs lower dose to limit side effects | first=Deena | last=Beasley | editor-first=Bill | editor-last=Berkrot | work=Reuters| date=June 24, 2025}}</ref> However, patients that continued to take the drug lost approximately 20% of their body weight.<ref>{{Cite news | url=https://www.statnews.com/2025/06/23/amgen-maritide-obesity-drug-trial-discontinuations-side-effects-dosing-changes/ | title=Amgen's obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing | first=Elaine | last=Chen | work=Stat | date=June 23, 2025}}</ref>

In April 2025, the company announced a $900 million expansion of its facility in New Albany, Ohio.<ref>{{Cite news | url=https://www.bizjournals.com/columbus/news/2025/04/25/amgen-new-albany-expansion.html | title=Amgen to invest $900 million in New Albany expansion, nearly doubling job creation | first=Carrie | last=Ghose | work=American City Business Journals | date=April 25, 2025 | url-access=subscription}}</ref> In September 2025, it announced plans to build a $600 million research center in Thousand Oaks, California.<ref>{{Cite news | url=https://www.vcstar.com/story/news/local/2025/09/03/amgen-to-build-600m-research-center-in-thousand-oaks/85940819007/ | title=Amgen to build $600M research center in Thousand Oaks | first=Tony | last=Biasotti | work=Ventura County Star | date=September 3, 2025}}</ref>

=== Acquisition history === {{hidden start|toggle=left|title=The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):|titlestyle=background:white;}} {{Tree list}} *'''Amgen Inc.''' (Founded 1983 as Applied Molecular Genetics) **Synergen Inc (Acq 1994)<ref>{{cite news | url=https://www.latimes.com/archives/la-xpm-1994-11-19-fi-64446-story.html | title=Amgen to Acquire Synergen in $239-Million Biotech Deal | last=Olmos | first=David | work=Los Angeles Times | date=November 19, 1994 | url-access=limited}}</ref> **Kinetix Pharmaceuticals Inc (Acq 2000)<ref>{{cite news | url=https://www.latimes.com/archives/la-xpm-2000-oct-24-me-41036-story.html |title=Amgen Agrees to Buy Drug Maker Kinetix | last=Murphy | first=Barbara | work=Los Angeles Times | date=October 24, 2000 | url-access=limited}}</ref> **Immunex Corporation (Acq 2002) **Tularik Inc (Acq 2004) **Abgenix Inc (Acq 2006) **Avidia Inc (Acq 2006)<ref>{{cite news |url=https://www.wsj.com/articles/SB115953920781877969 |title=Amgen Agrees to Acquire Biotech Company Avidia |work=The Wall Street Journal |date=September 29, 2006 | url-access=subscription}}</ref> **Alantos Pharmaceuticals (Acq 2007)<ref>{{cite news |url=https://www.technologynetworks.com/drug-discovery/news/amgen-to-acquire-alantos-pharmaceuticals-186303 |title=Amgen to Acquire Alantos Pharmaceuticals | work=Technology Networks | date=June 8, 2007}}</ref> **Ilypsa Inc (Acq 2007)<ref>{{cite news |url=https://www.genengnews.com/news/amgen-to-acquire-ilypsa-for-420m/ |title=Amgen to Acquire Ilypsa for $420M | work=Genetic Engineering and Biotechnology News |date=June 5, 2007}}</ref> **BioVex Group Inc (Acq 2011) **Micromet Inc (Acq 2012) **Mustafa Nevzat İlaç (Acq 2012) **KAI Pharmaceuticals (Acq 2012) **deCODE genetics (Acq 2012) **Onyx Pharmaceuticals (Acq 2013) ***Proteolix(Acq 2009) **NextCODE genetics (Spun off 2013) **Dezima Pharma (Acq 2015) **Catherex (Acq 2015)<ref>{{cite news | url=https://www.fiercebiotech.com/biotech/medigene-ag-amgen-acquires-medigene-spin-off-catherex | title=Medigene AG: Amgen acquires Medigene spin-off Catherex | work=FierceBiotech | date=December 21, 2015}}</ref> **Nuevolution AB (Acq 2019) **Otezla (apremilast) (Acq 2019)<ref>{{cite news | url=https://www.reuters.com/article/us-bristol-myers-divestiture-amgen/amgen-to-buy-celgene-psoriasis-drug-otezla-for-13-4-billion-idUSKCN1VG102 | title=Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion | last1=Erman | first1=Michael | last2=Mishra |first2=Manas | work=Reuters | date=August 26, 2019}}</ref> **Five Prime Therapeutics (Acq 2021)<ref>{{cite news |url=https://www.fiercebiotech.com/biotech/amgen-pays-a-premium-for-five-prime-therapeutics-a-1-9b-cash-deal |title=Prime time for Five Prime as Amgen snaps up this once-moribund biotech for $1.9B and its phoenix-from-the-flames cancer asset |last=Adams |first=Ben |work=FierceBiotech | date=March 4, 2021}}</ref> **Rodeo Therapeutics Corporation (Acq 2021)<ref>{{cite news | url=https://www.fiercebiotech.com/biotech/amgen-drops-55m-upfront-for-rodeo-therapeutics-and-its-prostaglandin-blockers | title=Amgen saddles up with Rodeo for a $55M trek into regenerative medicine |last=Idrus |first=Amirah Al |work=FierceBiotech | date=March 30, 2021}}</ref> **Teneobio (Acq 2021) **ChemoCentryx (Acq 2022)<ref>{{cite news |url=https://www.genengnews.com/topics/drug-discovery/therapeutics/autoimmune-disease-drugs/amgen-to-acquire-chemocentryx-for-3-7b-bolstering-autoimmune-portfolio/ |last=Philippidis |first=Alex |title=Amgen to Acquire ChemoCentryx for $3.7B, Bolstering Autoimmune Portfolio | work=Genetic Engineering and Biotechnology News |date=August 5, 2022}}</ref> **Horizon Therapeutics (Acq 2023) ***Vidara Therapeutics International (Acq 2014) ***Hyperion Therapeutics (Acq 2015) ***Crealta Holdings (Acq 2015) ***Raptor Pharmaceutical (Acq 2016) ***River Vision Development Corp. (Acq 2017) ***Viela Bio Inc (Acq 2021)<ref>{{cite news |url=https://www.biopharmadive.com/news/horizon-acquires-astrazeneca-spinout-viela-bio/594265/ |last1=Bell |first1=Jacob |last2=Fidler |first2=Ben |title=Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca |work=Biopharma Dive | publisher=Informa |date=February 1, 2021}}</ref> {{Tree list/end}} {{hidden end}}

==Corporate affairs== ===Sponsorships=== In December 2023, Amgen became the title sponsor of the Irish Open in golf, renaming it the Amgen Irish Open.<ref>{{Cite news | url=https://www.independent.ie/sport/golf/irish-open-sponsor-name-change-after-amgens-takeover-of-horizon/a2119441670.html | title=Irish Open sponsor name change after Amgen's takeover of Horizon | work=Irish Independent | date=December 14, 2023}}</ref>

===Philanthropy=== In October 2017, the Amgen Foundation pledged $3 million to Khan Academy to support the development of free online biology lessons.<ref>{{cite news |url=https://cheddar.com/media/khan-academy-founder-says-m-grant-will-help-tackle-inequities-in-virtual-education |last=Vuocolo |first=Alex |title=Khan Academy Founder Says $3M Grant Will Help Tackle Inequities in Virtual Education |work=Cheddar |date=June 23, 2020}}</ref><ref>{{cite news |url=https://www.vcstar.com/story/news/education/2017/10/29/amgen-foundation-awards-khan-academy-3-million-support-development-biology/777379001/ |title=Amgen Foundation awards Khan Academy $3 million to support development of biology |last=D'Angelo |first=Alexa |work=Ventura County Star |date=October 29, 2017}}</ref> In July 2020, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning.<ref>{{cite news |url=https://philanthropynewsdigest.org/news/amgen-foundation-awards-3-million-to-khan-academy2 |title=Amgen Foundation awards $3 million to Khan Academy |work=Candid |date=July 24, 2020}}</ref><ref>{{cite news |url=https://www.usatoday.com/story/tech/2020/07/30/khan-academy-ceo-sal-khan-prepping-fall-virtual-learning/5525480002/ |title=Q&A: Khan Academy CEO Sal Khan on the new school year and virtual learning |last=Molina | first=Brett |work=USA Today |date=July 30, 2020}}</ref>

In January 2020, the Amgen Foundation and Harvard University debuted LabXchange, a free online science education platform.<ref>{{cite news |url=https://campustechnology.com/articles/2020/01/24/amgen-and-harvard-launch-free-online-science-ed-platform.aspx |last=Kelly |first=Rhea |title=Amgen and Harvard Launch Free Online Science Ed Platform -- Campus Technology |work=Campus Technology |date=January 24, 2020}}</ref><ref>{{cite news | url=https://www.thecrimson.com/article/2020/4/8/harvard-coronavirus-labxchange/ |title=Harvard's LabXChange Provides Platform for Remote Scientific Learning During Pandemic |last1=Kahn |first1=Natalie L. |last2=Wang |first2=Andy Z. | work=The Harvard Crimson |date=April 8, 2020}}</ref> Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March.<ref>{{cite news | url=https://philanthropynewsdigest.org/news/amgen-at-t-others-announce-commitments-for-covid-19-response | title=Amgen, AT&T, Others Announce Commitments for COVID-19 Response |work=Candid | date=March 25, 2020}}</ref>

In November 2021, Amgen awarded a $2 million grant to the CDC Foundation to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for cancer treatments.<ref>{{Cite web | title=CDC Foundation Active Programs October 1, 2020 – September 30, 2021 | url=https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline | work=CDC Foundation | date=December 9, 2021 | archive-url=https://web.archive.org/web/20220115161004/https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline | archive-date=January 15, 2022 | url-status=live}}</ref>

==Products== Amgen's approved drugs or therapeutic biologicals include:

*Aimovig (erenumab-aooe) for migraine headaches (FDA approved May 2018)<ref>{{cite journal |url=https://www.ahdbonline.com/issues/2019/march-2019-vol-12-tenth-annual-payers-guide/2735-aimovig-erenumab-aooe-first-cgrp-receptor-antagonist-approved-for-the-prevention-of-migraine-in-adults |last=Raedler |first=Lisa A. |title=Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults |journal=American Health & Drug Benefits |volume=12 |date=April 15, 2019}}</ref> *Amjevita (adalimumab)<ref name="Staton"/> (FDA approved September 2016) *Aranesp (darbepoetin alfa) for anemia (FDA approval in September 2001)<ref>{{cite news | url=https://www.nytimes.com/2001/09/19/business/technology-fda-approves-new-version-of-amgen-drug.html | title=F.D.A. Approves New Version of Amgen Drug | last=Pollack | first=Andrew | work=The New York Times | date=September 19, 2001 | url-access=limited}}</ref> *Blincyto (blinatumomab for the treatment of acute lymphoblastic leukemia)<ref>Food and Drug Administration December 3, 2014 [https://web.archive.org/web/20150128234353/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm425597.htm FDA Press release: Blinatumomab]</ref> *Corlanor (ivabradine) *Enbrel (etanercept) for various forms of arthritis *Epogen (erythropoietin) for anemia *Evenity (romosozumab-aqqg) for osteoporosis *Imlygic (talimogene laherparepvec) for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma recurrent after initial surgery (FDA approved October 2015)<ref>{{Cite news | url=https://www.reuters.com/article/idUSKCN0SL2YG/ | title=FDA approves Amgen's injected immunotherapy for melanoma | last=Berkrot | first=Bill | work=Reuters | date=October 27, 2015}}</ref> *Kanjinti (trastuzumab-anns)<ref name="Kanjinti approval"/> (FDA approved June 2019) *Krystexxa (pegloticase) *Kyprolis (carfilzomib) *Lumakras (sotorasib)<ref name="Lumakras approval"/> *Mvasi (bevacizumab-awwb)<ref name="Mvasi approval"/> *Neulasta (pegfilgrastim) for neutropenia (FDA approved 2002)<ref>{{cite news | url=https://www.thepharmaletter.com/article/fda-approves-amgen-s-new-generation-filgrastim-product-neulasta |title=FDA approves Amgen's new-generation filgrastim product, Neulasta |work=www.thepharmaletter.com |date=November 2, 2002}}</ref> *Neupogen (granulocyte colony-stimulating factor) for neutropenia *Nplate (romiplostim) for chronic immune thrombocytopenic purpura (FDA approved 2008)<ref>{{cite news | url=https://www.reuters.com/article/us-amgen/u-s-fda-approves-amgens-blood-platelet-booster-idUSN2251359920080822 | title=U.S. FDA approves Amgen's blood platelet booster |last=Heavey | first=Susan | work=Reuters | date=August 22, 2008}}</ref><ref>{{cite journal | last1=Jamali | first1=Faranak | last2=Lemery | first2=Steven | last3=Ayalew | first3=Kassa |last4=Robottom | first4=Suzanne | last5=Robie-Suh | first5=Kathy | last6=Rieves | first6=Dwaine |last7=Pazdur |first7=Richard |date=July 2009 | title=Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura |journal=Oncology (Williston Park, N.Y.) | volume=23 | issue=8 | pages=704–709 |issn=0890-9091 |pmid=19711585 }}</ref> *Otezla (apremilast)<ref>{{cite news | url=https://www.pmlive.com/pharma_news/amgen_shares_new_otezla_data_at_american_academy_of_dermatology_congress_2022_1389524 | title=Amgen shares new Otezla data at American Academy of Dermatology congress 2022 | last=Jeffries | first=Fleur | work=PMLive | date=March 28, 2022}}</ref> *Parsabiv (etelcalcetide) *Prolia (denosumab) for postmenopausal osteoporosis *Repatha (evolocumab) *Riabni (rituximab-arrx)<ref name="Riabni approval"/> *Sensipar/Mimpara (cinacalcet for primary and secondary hyperparathyroidism, a mineral metabolism complication common in patients with kidney failure) (FDA approved 2004)<ref>{{cite news | url=https://www.clinician.com/articles/6766-new-fda-approvals | title=New FDA Approvals | work=clinician.com | date=May 1, 2004}}</ref><ref>{{cite web | title=Drug Approval Package: Sensipar (Cinacalcet HCI) NDA #021688 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm | work=U.S. Food and Drug Administration | archive-url=https://web.archive.org/web/20130218063129/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm | archive-date=February 18, 2013 | url-status=live}}</ref> *Tepezza (teprotumumab) *Tezspire (tezepelumab-ekko)<ref name="Dunleavy"/> *Tavneos (avacopan) *Uplizna (inebilizumab) *Vectibix (panitumumab for colon cancer) (FDA approved 2006)<ref>{{cite journal |last1=Giusti |first1=Ruthann M. | last2=Shastri | first2=Kaushikkumar A. |last3=Cohen |first3=Martin H. |last4=Keegan |first4=Patricia |last5=Pazdur | first5=Richard | date=May 2007 | title=FDA drug approval summary: panitumumab (Vectibix) |journal=The Oncologist |volume=12 | issue=5 | pages=577–583 | doi=10.1634/theoncologist.12-5-577 |issn=1083-7159 |pmid=17522246 |s2cid=9376408 }}</ref> *Xgeva (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone in adults with bone metastases from solid tumors)

===Products developed and then sold=== * Kepivance (palifermin for oral mucositis, sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008<ref name=BiovitriumDeal>{{Cite press release | url=https://www.globenewswire.com/news-release/2008/12/16/23521/0/en/Biovitrum-and-Amgen-Announce-Close-of-Product-Acquisition-Deal.html | title=Biovitrum and Amgen Announce Close of Product Acquisition Deal | publisher=GlobeNewswire | date=December 16, 2008}}</ref> *StemGen (ancestim) for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells) (sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008)<ref name=BiovitriumDeal/> *Kineret (anakinra) for rheumatoid arthritis, exclusively licensed to Biovitrium, now Swedish Orphan Biovitrum, in December 2008<ref name=BiovitriumDeal/>

==Legal issues== In December 2012, Amgen plead guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints regarding the improper marketing of anemia drug Aranesp. According to the United States Department of Justice, Amgen sold the drug for off-label uses at dosages that the FDA had rejected or never approved.<ref>{{cite news | url=https://www.latimes.com/business/la-xpm-2012-dec-18-la-fi-amgen-plea-20121219-story.html | last=Terhune | first=Chad | title=Amgen pleads guilty to improper marketing of anemia drug Aranesp |work=Los Angeles Times | date=December 18, 2012 | url-access=limited}}</ref><ref>{{Cite press release | url=https://www.justice.gov/archives/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal | title=Amgen Inc. Pleads Guilty to Federal Charge in Brooklyn, NY.;Pays $762 Million to Resolve Criminal Liability and False Claims Act Allegations | publisher=United States Department of Justice | date=December 19, 2012}}</ref>

In May 2025, a jury awarded Regeneron $406 million from Amgen, which engaged in anticompetitive practices to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's Praluent.<ref>{{Cite news | url=https://www.reuters.com/sustainability/boards-policy-regulation/amgen-owes-406-million-monopolizing-cholesterol-drug-market-us-jury-says-2025-05-15/ | title=Amgen owes $406 million for monopolizing cholesterol drug market, US jury says | first=Blake | last=Brittain | editor-first=Cynthia | editor-last=Osterman | work=Reuters | date=May 15, 2025}}</ref>

==See also== {{Portal|California|Companies}} * ''Kirin-Amgen v Hoechst Marion Roussel'', a UK patent case decided by the House of Lords * ''Amgen Inc. v. Harris'', a United States Supreme Court case on employment law. *Evolocumab *''Amgen Inc v. Sanofi'', a United States Supreme Court case on patent enablement.

== References == {{Reflist}}

==External links== {{Commons category}} *{{Official website|https://www.amgen.com/}} * {{OpenSecrets}} {{Finance links | name = Amgen | google = AMGN:NASDAQ | reuters = AMGN | sec_cik = 318154 | yahoo = AMGN }} {{Pharmaceutical companies of the United States}} {{Dow Jones Industrial Average companies}} {{NASDAQ-100}} {{S&P 500 companies}} {{Authority control}}

Category:Amgen Category:1980 establishments in California Category:1980s initial public offerings Category:Biotechnology companies established in 1980 Category:Biotechnology companies of the United States Category:Companies based in Thousand Oaks, California Category:Companies in the Dow Jones Global Titans 50 Category:Companies in the Dow Jones Industrial Average Category:Companies listed on the Nasdaq Category:Life sciences industry Category:Multinational companies headquartered in the United States Category:Pharmaceutical companies established in 1980 Category:Pharmaceutical companies of the United States Category:Pharmaceutical companies